A primary goal of human genetics is to identify DNA sequence variants that influence
biomedical traits, particularly those related to the onset and progression of human disease …

Financial Disclosure Ernst Lengyel disclosed that money was paid to his institution from
AbbVie (funding preclinical studies), NCI (RO1 grants), and the Ovarian Cancer Research …

Progress in ovarian cancer treatment lags behind other tumor types. With diagnosis usually
at an advanced stage, there is a high demand for reliable prognostic biomarkers capable of …

Abstract Background The 16th St. Gallen International Breast Cancer Conference 2019 in
Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies …

Despite advances in diagnosis and therapy, an individual with ovaries carries an
approximate 1 in 108 lifetime chance to die due to ovarian cancer (OC). Primary therapy …

Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (g BRCA1/2)-mutant
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …

PURPOSE To provide recommendations on genetic and tumor testing for women diagnosed
with epithelial ovarian cancer based on available evidence and expert consensus …

Germline alterations in many genes coding for proteins regulating DNA repair and DNA
damage response (DDR) to DNA double-strand breaks (DDSB) have been recognized as …

A systematic review was conducted, summarizing international BRCA 1 or 2 (BRCA1/2)
mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N= 7) and …

PARP inhibitors have been approved for the treatment of metastatic breast cancer in
germline BRCA mutation (g BRCA m) carriers. The recent OlympiA trial demonstrated …